The Commission will address to the SCF [8] a request for evaluation of the "non dioxin-like PCB's ("classical" or "non-coplanar" PCBs) which have another toxicological profile, which circulate more easily through muscles and blood and affect directly the nervous system and brain development and which could be several orders of magnitude more concentrated than dioxins in aquatic biota such as fish and shellfish.

2. Where, in the interests of public health, the laws of a Member State so provide, the competent authorities may require the marketing authorization holder for medicinal products derived from human blood or human plasma to submit samples from each batch of the bulk and/or the medicinal product for testing ►M4 by an Official Medicines Control Laboratory or a laboratory that a Member State has designated for that purpose ◄ before being released into free circulation, unless the competent authorities of another Member State have previously examined the batch in question and declared it to be in conformity with the approved specifications.

2. Where, in the interests of public health, the laws of a Member State so provide, the competent authorities may require the marketing authorization holder for medicinal products derived from human blood or human plasma to submit samples from each batch of the bulk and/or the medicinal product for testing by a State laboratory or a laboratory designated for that purpose before being released into free circulation, unless the competent authorities of another Member State have previously examined the batch in question and declared it to be in conformity with the approved specifications.

The existence of a new European directive which provides for the same standards of quality in the individual Member States will facilitate the free movement of blood from one European Union country to another and remove uncalled-for restrictions on donors moving between countries.

Hormones are signalling molecules, which travel through the bloodstream and elicit responses in other parts of the body.

3. Where, in the interests of public health, the laws of a Member State so provide, the competent authorities may require persons responsible for marketing medicinal products derived from human blood or human plasma to submit samples from each batch of the bulk and/or finished product for testing by a State laboratory or a laboratory designated for that purpose before being released into free circulation, unless the competent authorities of another Member State have previously examined the batch in question and declared it to be in conformity with the approved specifications.